OverviewChartNewsTraderScreen

Morgan Stanley Knock-Out NBIX/  DE000ME4CFH1  /

Stuttgart
2024-11-12  9:11:36 PM Chg.0.00 Bid10:00:36 PM Ask10:00:36 PM Underlying Strike price Expiration date Option type
2.69EUR 0.00% -
Bid Size: -		 -
Ask Size: -		 Neurocrine Bioscienc... 99.0198 USD 2078-12-31 Call
GlobeNewswire 09-02 Nxera Pharma to Receive US$35 Million from Neurocrine Biosciences upon Positive Phase 2 Data for Par...
GlobeNewswire 08-29 Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire 08-29 Voyager Therapeutics to Present at Multiple Upcoming Investor Conferences
GlobeNewswire 08-28 Nxera Pharma Notes Positive Phase 2 Data for Partnered Schizophrenia Candidate NBI-1117568
GlobeNewswire 08-09 Nxera Pharma Operational Highlights and Consolidated Results for the Second Quarter and First Half 2...
GlobeNewswire 08-08 Xenon Reports Q2 2024 Financial Results and Business Update
GlobeNewswire 08-07 Voyager Therapeutics to Present at Canaccord Genuity 44th Annual Growth Conference & Private Company...
GlobeNewswire 08-06 Voyager Therapeutics Reports Second Quarter 2024 Financial and Operating Results
GlobeNewswire 07-30 Voyager Therapeutics Announces Second Quarter 2024 Conference Call and Webcast
GlobeNewswire 07-23 Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire 07-09 Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire 06-13 Voyager Therapeutics to Present at Multiple Virtual Investor Conferences
GlobeNewswire 06-13 Voyager Therapeutics Announces Appointment of Nathan Jorgensen as Chief Financial Officer
GlobeNewswire 05-16 Voyager Therapeutics Announces First Participants Dosed in Single Ascending Dose Trial of VY-TAU01 f...
GlobeNewswire 05-13 Voyager Therapeutics Reports First Quarter 2024 Financial and Operating Results
GlobeNewswire 05-09 Xenon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire 05-09 Nxera Pharma’s partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of...
GlobeNewswire 05-09 Nxera Pharma Operational Highlights and Consolidated Results for the First Quarter 2024
GlobeNewswire 05-08 Voyager Therapeutics Presents Data for Second-Generation, TRACER™-Generated Capsids and CNS Gene The...
GlobeNewswire 05-06 Voyager Therapeutics Announces First Quarter 2024 Conference Call and Webcast
GlobeNewswire 04-22 Voyager Therapeutics to Present Broad Set of Translational Data Supporting IV-Delivered, CNS Gene Th...
GlobeNewswire 04-16 Sentia Medical Sciences and Neurocrine Biosciences Extend Research Collaboration to Discover Novel C...
GlobeNewswire 04-16 Voyager Therapeutics Announces Selection of Development Candidate for GBA1 Program in Collaboration ...
GlobeNewswire 04-16 Nxera Pharma Notes Successful Development Progress of Partnered Schizophrenia Candidate NBI-1117568
GlobeNewswire 03-26 Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)